NCT05954559View on ClinicalTrials.gov

High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment

PHASE4RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Myocardial Fibrosis
Interventions
DRUG

Elucirem (Gadopiclenol)

Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging.

Trial Locations (2)

21202

RECRUITING

Johns Hopkins Center for Advanced Imaging and Research Science, located in the Science + Technology Park at 1812 Ashland Avenue, Baltimore, MD., Baltimore

21205

NOT_YET_RECRUITING

Johns Hopkins School of Medicine, Baltimore

Sponsors

Collaborators (1)

Guerbet
All Listed Sponsors
collaborator

Guerbet

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT05954559 - High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment | Biotech Hunter | Biotech Hunter